Page 6 - Dr Reddy's
Dr Reddy's reaping benefits of domestic market focus, outperforms peers
Firm has outperformed domestic pharma market in 7 of last 8 quarters
 "Dr Reddy's reaping benefits of domestic market focus, outperforms peers")
Dr Reddy's launches cancer treatment drug Bortezomib in the US market
Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals
 "Dr Reddy's launches cancer treatment drug Bortezomib in the US market")
Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts
Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites
 "Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts")
Develop entire value chain: Dr Reddy's MD tells pharma companies
US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad
 "Develop entire value chain: Dr Reddy's MD tells pharma companies")
Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad
According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact
 "Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad")
Sharp earnings downgrades for Dr Reddy's, Zee Entertainment and IOC
Among other Nifty companies, ZEEL has seen an earnings cut of over 8%
 "Sharp earnings downgrades for Dr Reddy's, Zee Entertainment and IOC")
Domestic-oriented companies on fund managers' radar, says analyst
Further, fund managers say the markets could continue to remain polarised as growth companies are likely to fetch a premium, especially when the economy is going through a trough
 "Domestic-oriented companies on fund managers' radar, says analyst")
PSAI segment decline pulls down Dr Reddy's Q1 show
Earnings were driven by one-off gains
 "PSAI segment decline pulls down Dr Reddy's Q1 show")
Dr Reddy's launches therapeutic equivalent of Vitamin K1 in US
Dr Reddy's Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules is available in 1 ml Ampule containing 10 mg/ml of Phytonadione
 "Dr Reddy's launches therapeutic equivalent of Vitamin K1 in US")
How a change in proprietary strategy is yielding results for Dr Reddy's
As reduced commercialisation costs add to profitability, the growth in India and emerging markets is also encouraging
 "How a change in proprietary strategy is yielding results for Dr Reddy's")
Dr Reddy's sells US rights of branded neurology products to Upsher-Smith
The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act of the US government
 "Dr Reddy's sells US rights of branded neurology products to Upsher-Smith")
Dr Reddy's to sell rights of 2 neurology drugs to Upsher-Smith for $110 mn
Dr Reddy's said it will receive sales-based royalties on a quarterly basis
 "Dr Reddy's to sell rights of 2 neurology drugs to Upsher-Smith for $110 mn")
New plaque psoriasis drug study yields positive results: Dr Reddy's
The detailed safety and efficacy data from the study would be presented in future dermatology conferences
Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook
Lower traction in US sales, sequential decline in other key geographies and subdued margin gains disappointed the Street
 "Dr Reddy's: Some disappointment in Q4, but generics focus improves outlook")
Dr Reddy's recalls anti-seizure drug in the US market
According to information posted on the US Food and Drug Administration(USFDA), the company initiated a voluntary recall of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April
Dr Reddy's eyeing volume and value growth in the US
Firm is adding volume-driven products such as the recent acquisition of 42 ANDAs. The portfolio has over 30 injectables and an addressable market size of $645 mn
 "Dr Reddy's eyeing volume and value growth in the US")
Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US
The company said it has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products
Focus on India, emerging markets could drive Dr Reddy's rerating
These markets get a higher valuation compared to the US
Dr Reddy's may take six months to resolve issues flagged by US FDA
Compliance norms to keep Dr Reddy's under pressure
US insurer names Dr Reddy's, dozens of other drug firms in price fixing row
The complaint involves 30 generic drugs, 42 companies; DRL denies wrongdoing, says will vigorously defend itself